Genomeditech (Shanghai) Co.,Ltd.
Order: 021-68455258/50432826/50432825
Toll-free: 400 627 9288
Email: service@genomeditech.com

Human DLL4 Protein; His Tag

Product Information

Product Name	Human DLL4 Protein; His Tag
Storage temp	Store at ≤ -70℃, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Catalog# / Size	**GM-88575RP-100 / 100 μg** **GM-88575RP-1000 / 1 mg**

Protein Information

Alternative Names	Delta4
Source	Human DLL4 Protein; His Tag (GM-88575RP) is expressed from human 293 cells (HEK-293). It contains AA Ser 27 - Pro 524 (Accession # Q9NR61-1). This protein carries a His tag at the C-terminus.
Purity	> 95% as determined by SDS-PAGE
Endotoxin	< 1 EU/μg, determined by LAL gel clotting assay
Predicted Mol Mass	55.1 KDa
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Description	DLL4 protein is a transmembrane ligand that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. It is encoded by the *DLL4* gene and is a critical regulator of cell fate determination, angiogenesis, and vascular development. DLL4 protein is primarily expressed in the vascular endothelium and plays a non-redundant role in arterial specification and sprouting angiogenesis during embryonic development. DLL4 protein regulates the activity of endothelial cells and other cell types by binding to the Notch1 and Notch4 receptors on adjacent cells. The DLL4/Notch signaling pathway is essential for coordinating cell differentiation, proliferation, and migration, making it a key mediator of vascular patterning and homeostasis. Research indicates that DLL4 protein plays a significant role in pathological angiogenesis, particularly in tumor growth and progression. Its expression is often upregulated in the tumor vasculature, where it promotes non-productive, dysfunctional blood vessel formation. This mechanism contributes to tumor immune evasion and resistance to anti-angiogenic therapies, positioning DLL4 as a promising therapeutic target for cancer treatment, either alone or in combination with other immunotherapies.

SDS-PAGE



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA



Human DLL4 Protein; His Tag (Catalog # GM-88575RP) was immobilized at 2 μg/ml (100 μL/well). Increasing concentrations of Anti-DLL4 hIgG2 Antibody (Navicixizumab) (Catalog # GM-51815AB) were added.



Human DLL4 Protein; His Tag (Catalog # GM-88575RP) was immobilized at 2 μg/ml (100 μL/well). Increasing concentrations of Anti-DLL4 hIgG1 Antibody (MLCK-2(ABL-001) (Catalog # GM-51820AB) were added.

Version:4.0

Genomeditech (Shanghai) Co.,Ltd.
Order: 021-68455258/50432826/50432825
Toll-free: 400 627 9288
Email: service@genomeditech.com

Bioactivity-ELISA

0.2 μg Human DLL4 Protein; His Tag of per well



Human DLL4 Protein; His Tag (Catalog # GM-88575RP) was immobilized at 2 μg/ml (100 μL/well). Increasing concentrations of Anti-DLL4 hIgG2 Antibody (demcizumab) (Catalog # GM-88253AB) were added.